LLDAS and clinical remission
| n=51; 700 visits, median follow-up 1106 days | LLDAS | CR on Tx | CR off Tx |
| Status ever achieved | 51 (100%) | 27 (52.9%) | 11 (21.6%) |
| Time to status in days, median (range) | 186 (28–846) | 415 (40–1585) | 536 (51–2103) |
| Time in status in days, median (range) | 693 (78–2676) | 176 (35–1198) | 176 (98–945) |
| % of time in status during follow-up, median (range) | 72.1 (11.6–98.5) | 17.9 (5–73.6) | 17.4 (4.1–88.6) |
| Number (%) of patient in status >50% of follow-up time | 37 (72.5) | 4 (14.8) | 1 (9.1) |
| Organ domains still active at visits not in LLDAS (N=195/700 visits) | BILAG-2004 | SELENA-SLEDAI | |
| Constitutional | 36 (18.5%) | Constitutional | 19 (9.7%) |
| Mucocutaneous | 110 (56.4%) | Mucocutaneous | 119 (61.0%) |
| Neuropsychiatric | 2 (1.0%) | Neuropsychiatric | 1 (0.5%) |
| Musculoskeletal | 55 (28.2%) | Musculoskeletal | 15 (7.7%) |
| Cardiorespiratory | 19 (9.7%) | Cardiorespiratory | 11 (5.6%) |
| Renal | 91 (46.7%) | Renal | 112 (57.4%) |
| Haematological | 123 (63.1%) | Haematological | 160 (82.1%) |
| Gastrointestinal | 15 (7.7%) | Immunological | 81 (41.5%) |
| Ophthalmological | 3 (1.5%) | Ophthalmological | 0 (0%) |
SELENA-SLEDAI domains are scored accordingly: constitutional (fever), mucocutaneous (vasculitis, rash, alopecia, mucosal ulcers), neuropsychiatric (psychosis, seizure, organic brain syndrome, cranial nerve disorders, lupus headache, CVA), musculoskeletal (arthritis, myositis), cardiorespiratory (pleurisy, pericarditis), renal (urinary casts, haematuria, proteinuria, pyuria), haematological (low complement, thrombocytopenia, leucopenia), immunological (increased DNA binding), ophthalmological (visual disturbance).
BILAG, British Isles Lupus Assessment Group; CR, clinical remission; LLDAS, Low Lupus Disease Activity State; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus National Assesment-SLE disease Activity Index; Tx, treatment.